Sugammadex

Heptakis(2,3,6-tri-O-benzoyl)-beta-cyclodextrin

Heptakis(2,3,6-tri-O-methyl)-beta-cyclodextrin

DIMEB

Sugammadex is one of the greatest successes in the history of cyclodextrins. There is an increasing interest for this product and for the development of Sugammadex since the approval by the FDA resulted in a 3-4-fold increase in the global sales of the product. SGM is used in anesthesia as an injectable an...

Dexolve is the first generic USP and EP-conform Betadex Sulfobutyl Ether Sodium for:• solubility enhancement (10 to 100,000 fold) • Improvement of chemical stability • Increased bioavailability, facilitated delivery • Reduced aggregation • Moderate irritationor reduced side-effects • Maximiz...

 HPBCD (EP, USP/NF)

alfadex, alfa-cyclodextrin (EP, USP/NF)

ACD, alfadex

acd, alfa-cyclodextrin (EP, USP/NF)

ACD, alfadex (EP, USP/NF)

betadex, beta-cyclodextrin (EP, USP/NF)

BCD, betadex (EP, USP/NF)

CycloLab Cyclodextrin Research and Development Ltd. is a private SME with the focus on cyclodextrin research and development for over 30 years. We are working in the fields of pharmaceutical, cosmetic and food industry, agrochemical, environmental and analytical applications of cyclodextrins.

After a precise development work CycloLab established and validated the production of pharma grade Betadex Sulfobutyl Ether Sodium formulation excipient (SBECD, DexolveTM) in 2008. This cyclodextrin is the main component of several commercial formulations worldwide acting as a solubility and stability enhancer.
DMF documentations were filed to the FDA (DMF No. 21922)in 2008, to Health Canada (DMF No. 2009-080) in 2009 and to China CDE in 2019 (No.F20190000489), all maintained ever since. In addition, CycloLab is a registered manufacturer of the Betadex Sulfobutyl Ether Sodium in the EudraGMDP database.

The facility is dedicated to the production of SBECD with multiple tons annual capacity (over 350 kg/batch). Our proprietary technology is extremely robust, no OOS results have been obtained after 150 manufactured batches. The production is carried out according to cGMP (OGYÉI-57792-7/2018) and ISO 9001 and the produ...

CycloLab, being involved in the fight, manufactures the critical excipient: sulfobutyl-ether-BCD (SBECD, Dexolve™) that enables Remdesivir to work. The unexpected and sudden outbreak along with the quick spread of the coronavirus-disease and rapid increase of the cases draw a sudden need for Dexolve.

Cyclolab's brochure on services

Cyclolab's brochure on Dexolve (SBECD)

Cyclolab company presentation